NYSE: BMY

Price$55.77 Change -0.59 %Change -1.05% Volume: 7,623,059 20 minute delay March 23, 2017

Analyst Coverage

Firm Analyst
Argus Research Company David Toung
Atlantic Equities Richard  Purkiss
Barclays Capital Geoff Meachem and Paul Choi
Bank of America Merrill Lynch Colin Bristow
Berenberg Laura Sutcliffe
BMO Capital Markets - US Alex Arfaei
Citi Andrew Baum
Cowen and Company Steve Scala
Credit Suisse Vamil Divan
Deutsche Bank Gregg Gilbert
Evercore ISI Mark Schoenebaum 
Goldman Sachs Jami  Rubin
Guggenheim Securities Charles Anthony Butler
Hilliard Lyons Stephen A. O'Neil
Jefferies & Co. Jeffrey Holford
J.P. Morgan Chris  Schott
Leerink Swann, LLC Seamus Fernandez
MKM Partners Jon LeCroy
Morgan Stanley David  Risinger
Morningstar, Inc. Damien  Conover
Sanford C. Bernstein & Co., LLC Tim Anderson
Suntrust Robinson Humphrey John T. Boris
UBS Marc  Goodman
William Blair & Company, LLC John Sonnier

* This page is hosted by Q4 Web Systems. Bristol-Myers Squibb does not monitor, endorse or accept responsibility for the content posted on this page by Q4 Web Systems.

This list includes those analysts that follow Bristol-Myers Squibb and whose research and estimates are included in consensus estimates with First Call or FactSet. Please note that any opinions, estimates or forecasts regarding Bristol-Myers Squibb's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Bristol-Myers Squibb or its management. Bristol-Myers Squibb does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Materials on this website may contain information about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements contained on this website should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in the company’s most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. These documents are available from the Securities and Exchange Commission, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations.

In addition, any information contained on this website was current as of the date presented and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change, whether as a result of new information, future events or otherwise. Consequently, the company will not update the information contained on the website and investors should not rely upon the information as current or accurate after the presentation date. The website may also contain certain non-GAAP financial measures, adjusted to include certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures for a particular quarterly period are available on the company’s website at www.bms.com.